Prognosis
Treatment of HCL with purine analogues (cladribine or pentostatin) has demonstrated high rates of complete response (>75%) and prolongation of disease-free survival. However, relapse is reported in approximately 50% of patients in long-term studies. (1)
The promises of new therapies suggest that most patients can now expect to survive for more than 10 years. With previous methods, median survival was 6 years, with only one-third of patients surviving longer than 10 years. (2)
Reference
- Else M, Dearden CE, Catovsky D. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015 Dec;28(4):217-29.
- Paillassa J, Cornet E, Noel S, et al. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 2020 May 27;10(5):62.
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page